{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:42Z","timestamp":1792718322600,"version":"4.5.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s40265-019-01141-w","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T04:02:38Z","timestamp":1560139358000},"page":"1053-1063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy"],"prefix":"10.1007","volume":"79","author":[{"given":"Sherman","family":"Picardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1551-9054","authenticated-orcid":false,"given":"Cynthia H.","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1756283X10361304","volume":"3","author":"E Langholz","year":"2010","unstructured":"Langholz E. Current trends in inflammatory bowel disease: the natural history. Ther Adv Gastroenterol. 2010;3:77\u201386.","journal-title":"Ther Adv Gastroenterol."},{"key":"1141_CR2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2036.2007.03397.x","volume":"26","author":"ZS Heetun","year":"2007","unstructured":"Heetun ZS, Byrnes C, Neary P, O\u2019Morain C. Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26:513\u201333.","journal-title":"Aliment Pharmacol Ther"},{"key":"1141_CR3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.2006.108324","volume":"56","author":"J Cornish","year":"2007","unstructured":"Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830\u20137.","journal-title":"Gut"},{"key":"1141_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MIB.0000000000000060","volume":"20","author":"G Br\u00f6ms","year":"2014","unstructured":"Br\u00f6ms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1.","journal-title":"Inflamm Bowel Dis"},{"key":"1141_CR5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1756-0500-6-210","volume":"6","author":"M Ujihara","year":"2013","unstructured":"Ujihara M, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, et al. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis. BMC Res Notes. 2013;6:210.","journal-title":"BMC Res Notes."},{"issue":"9","key":"1141_CR6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ajg.2016.254","volume":"111","author":"A de Lima-Karagiannis","year":"2016","unstructured":"de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. The effects of active IBD during pregnancy in the era of novel IBD therapies. Am J Gastroenterol. 2016;111(9):1305\u201312.","journal-title":"Am J Gastroenterol."},{"key":"1141_CR7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","volume":"23","author":"H Kammerlander","year":"2017","unstructured":"Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, N\u00f8rg\u00e5rd B. The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1011\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"1141_CR8","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ecco-jcc\/jjw052","volume":"10","author":"ZR Gallinger","year":"2016","unstructured":"Gallinger ZR, Rumman A, Nguyen GC. Perceptions and attitudes towards medication adherence during pregnancy in inflammatory bowel disease. J Crohns Colitis. 2016;10:892\u20137.","journal-title":"J Crohns Colitis."},{"key":"1141_CR9","first-page":"6193275","volume":"2016","author":"VW-M Huang","year":"2016","unstructured":"Huang VW-M, Chang H-J, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, et al. Management of inflammatory bowel disease during pregnancy and breastfeeding varies widely: a need for further education. Can J Gastroenterol Hepatol. 2016;2016:6193275.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1141_CR10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/path.2651","volume":"220","author":"E Lever","year":"2010","unstructured":"Lever E, Sheer D. The role of nuclear organization in cancer. J Pathol. 2010;220:114\u201325.","journal-title":"J Pathol."},{"key":"1141_CR11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","volume":"339","author":"CP Braegger","year":"1992","unstructured":"Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet (London, England). 1992;339:89\u201391.","journal-title":"Lancet (London, England)."},{"issue":"2","key":"1141_CR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","volume":"81","author":"TT MacDonald","year":"1990","unstructured":"MacDonald TT, Hutchings P, Choy M-Y, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol. 1990;81(2):301\u20135.","journal-title":"Clin Exp Immunol."},{"key":"1141_CR13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","volume":"113","author":"M Chaparro","year":"2018","unstructured":"Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, et al. Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the Multicenter European TEDDY Study. Am J Gastroenterol. 2018;113:396\u2013403.","journal-title":"Am J Gastroenterol"},{"key":"1141_CR14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","volume":"30","author":"DM Knight","year":"1993","unstructured":"Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443\u201353.","journal-title":"Mol Immunol"},{"issue":"15","key":"1141_CR15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn\u2019s disease. N Engl J Med. 1997;337(15):1029\u201335.","journal-title":"N Engl J Med."},{"key":"1141_CR16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet (London, England). 2002;359:1541\u20139.","journal-title":"Lancet (London, England)."},{"key":"1141_CR17","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u201376.","journal-title":"N Engl J Med"},{"key":"1141_CR18","doi-asserted-by":"publisher","first-page":"985646","DOI":"10.1155\/2012\/985646","volume":"2012","author":"P Palmeira","year":"2012","unstructured":"Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. https:\/\/doi.org\/10.1155\/2012\/985646 .","journal-title":"Clin Dev Immunol."},{"key":"1141_CR19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-0897.1998.tb00064.x","volume":"40","author":"A Malek","year":"1998","unstructured":"Malek A, Sager R, Schneider H. Transport of proteins across the human placenta. Am J Reprod Immunol. 1998;40:347\u201351.","journal-title":"Am J Reprod Immunol"},{"issue":"3","key":"1141_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","volume":"11","author":"U Mahadevan","year":"2013","unstructured":"Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286\u201392. https:\/\/doi.org\/10.1016\/j.cgh.2012.11.011 (quiz e24).","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1141_CR21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","volume":"151","author":"M Julsgaard","year":"2016","unstructured":"Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151:110\u20139.","journal-title":"Gastroenterology"},{"key":"1141_CR22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/apt.14040","volume":"45","author":"CH Seow","year":"2017","unstructured":"Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1329\u201338.","journal-title":"Aliment Pharmacol Ther"},{"key":"1141_CR23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2015-309321","volume":"65","author":"A de Lima","year":"2016","unstructured":"de Lima A, Zelinkova Z, van der Ent C, Steegers EAP, van der Woude CJ. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65:1261\u20138.","journal-title":"Gut"},{"key":"1141_CR24","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","volume":"99","author":"JA Katz","year":"2004","unstructured":"Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385\u201392.","journal-title":"Am J Gastroenterol"},{"key":"1141_CR25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0016-5085(12)60561-7","volume":"142","author":"U Mahadevan","year":"2012","unstructured":"Mahadevan U, Martin CFSR. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142:149.","journal-title":"Gastroenterology"},{"issue":"9","key":"1141_CR26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107(9):1409\u201322. https:\/\/doi.org\/10.1038\/ajg.2012.218 .","journal-title":"Am J Gastroenterol."},{"key":"1141_CR27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/apt.12936","volume":"40","author":"P Deepak","year":"2014","unstructured":"Deepak P, Stobaugh DJ. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:1035\u201343.","journal-title":"Aliment Pharmacol Ther"},{"key":"1141_CR28","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","volume":"17","author":"F Schnitzler","year":"2011","unstructured":"Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846\u201354.","journal-title":"Inflamm Bowel Dis"},{"key":"1141_CR29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/apt.12833","volume":"40","author":"M Seirafi","year":"2014","unstructured":"Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, Allez M, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:363\u201373.","journal-title":"Aliment Pharmacol Ther"},{"key":"1141_CR30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ecco-jcc\/jjv234","volume":"10","author":"Z Shihab","year":"2016","unstructured":"Shihab Z, Yeomans ND, De Cruz P. Anti-tumour necrosis factor \u03b1 therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis. J Crohns Colitis. 2016;10:979\u201388.","journal-title":"J Crohns Colitis."},{"key":"1141_CR31","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","volume":"20","author":"N Narula","year":"2014","unstructured":"Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNF\u03b1 therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1862\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1141_CR32","doi-asserted-by":"crossref","first-page":"S773","DOI":"10.1016\/S0016-5085(16)32618-X","volume":"150","author":"B Truta","year":"2016","unstructured":"Truta B, Canner J, Efron J, Safar B. The effect of intrauterine exposure to biologics: two years follow up. Gastroenterology. 2016;150:S773.","journal-title":"Gastroenterology"},{"key":"1141_CR33","doi-asserted-by":"crossref","first-page":"S-1","DOI":"10.1016\/S0016-5085(14)60001-9","volume":"146","author":"U Mahadevan","year":"2014","unstructured":"Mahadevan U, Martin CF, Chambers C, Kane SV, Dubinsky M, Sandborn W, et al. Achievement of developmental milestones among offspring of women with inflammatory bowel disease: the PIANO Registry. Gastroenterology. 2014;146:S-1.","journal-title":"Gastroenterology."},{"issue":"3","key":"1141_CR34","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/ajg.2017.501","volume":"113","author":"M Chaparro","year":"2018","unstructured":"Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, et al. Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol. 2018;113(3):396\u2013403. https:\/\/doi.org\/10.1038\/ajg.2017.501 .","journal-title":"Am J Gastroenterol."},{"key":"1141_CR35","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","volume":"113","author":"M Luu","year":"2018","unstructured":"Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, et al. Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French national health insurance database (EVASION). Am J Gastroenterol. 2018;113:1669\u201377.","journal-title":"Am J Gastroenterol."},{"key":"1141_CR36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","volume":"9","author":"CJ van der Woude","year":"2015","unstructured":"van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107\u201324.","journal-title":"J Crohns Colitis."},{"key":"1141_CR37","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ajg.2013.12","volume":"108","author":"N Vande Casteele","year":"2013","unstructured":"Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962\u201371.","journal-title":"Am J Gastroenterol"},{"key":"1141_CR38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","volume":"150","author":"GC Nguyen","year":"2016","unstructured":"Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734\u2013757e1.","journal-title":"Gastroenterology."},{"issue":"4","key":"1141_CR39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.MIB.0000164023.10848.c4","volume":"11","author":"U Mahadevan","year":"2005","unstructured":"Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(4):395\u20139.","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"1141_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.fertnstert.2013.10.048","volume":"101","author":"R Ramonda","year":"2014","unstructured":"Ramonda R, Foresta C, Ortolan A, Bertoldo A, Oliviero F, Lorenzin M, et al. Influence of tumor necrosis factor \u03b1 inhibitors on testicular function and semen in spondyloarthritis patients. Fertil Steril. 2014;101(2):359\u201365. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.10.048 .","journal-title":"Fertil Steril."},{"key":"1141_CR41","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1136\/ard.2009.127423","volume":"69","author":"PM Villiger","year":"2010","unstructured":"Villiger PM, Caliezi G, Cottin V, Forger F, Senn A, Ostensen M. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis. 2010;69:1842\u20134.","journal-title":"Ann Rheum Dis"},{"key":"1141_CR42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3899\/jrheum.080554","volume":"36","author":"S Paschou","year":"2009","unstructured":"Paschou S, Voulgari PV, Vrabie IG, Saougou IG, Drosos AA. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol. 2009;36:351\u20134.","journal-title":"J Rheumatol"},{"key":"1141_CR43","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2013.171","volume":"108","author":"JP Gisbert","year":"2013","unstructured":"Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426\u201338.","journal-title":"Am J Gastroenterol"},{"key":"1141_CR44","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","volume":"155","author":"R Matro","year":"2018","unstructured":"Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155:696\u2013704.","journal-title":"Gastroenterology"},{"key":"1141_CR45","doi-asserted-by":"crossref","first-page":"S-149","DOI":"10.1016\/S0016-5085(12)60561-7","volume":"142","author":"U Mahadevan","year":"2012","unstructured":"Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis JD, et al. 865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142:S-149.","journal-title":"Gastroenterology."},{"key":"1141_CR46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1572-0241.2005.40785.x","volume":"100","author":"S Kane","year":"2005","unstructured":"Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol. 2005;100:102\u20135.","journal-title":"Am J Gastroenterol"},{"key":"1141_CR47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/CEG.S14558","volume":"4","author":"L Guidi","year":"2011","unstructured":"Guidi L, Pugliese D, Armuzzi A. Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Exp Gastroenterol. 2011;4:163\u201372.","journal-title":"Clin Exp Gastroenterol"},{"issue":"2","key":"1141_CR48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, Macintosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323\u201333 (quiz 591).","journal-title":"Gastroenterology."},{"key":"1141_CR49","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56:1232\u20139.","journal-title":"Gut"},{"key":"1141_CR50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"J-F Colombel","year":"2007","unstructured":"Colombel J-F, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"1141_CR51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, Colombel J, D\u2019Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257\u2013265.e1-3.","journal-title":"Gastroenterology."},{"key":"1141_CR52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","volume":"11","author":"U Mahadevan","year":"2013","unstructured":"Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti\u2013tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286\u201392.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"8","key":"1141_CR53","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ecco-jcc\/jjy058","volume":"12","author":"SL Kanis","year":"2018","unstructured":"Kanis SL, De Lima-Karagiannis A, Van Der Ent C, Rizopoulos D, Van Der Woude CJ. Anti-TNF levels in cord blood at birth are associated with anti-TNF type. J Crohn\u2019s Colitis. 2018;12(8):939\u201347. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy058 .","journal-title":"J Crohn\u2019s Colitis."},{"key":"1141_CR54","doi-asserted-by":"crossref","unstructured":"Johnson D, Jones K, Chambers C. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology. 2009;136(5) Supplement 1. Abstract 142.","DOI":"10.1016\/S0016-5085(09)60125-6"},{"key":"1141_CR55","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","volume":"36","author":"JD Carter","year":"2009","unstructured":"Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the food and drug administration database. J Rheumatol. 2009;36:635\u201341.","journal-title":"J Rheumatol"},{"key":"1141_CR56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/IMCRJ.S173826","volume":"11","author":"L van den Broek","year":"2018","unstructured":"van den Broek L, van der Werff-Ten Bosch J, Cortoos P-J, van Steijn S, van den Akker M. Severe neutropenia in a breastfed infant: a case report and discussion of the differential diagnosis. Int Med Case Rep J. 2018;11:333\u20137.","journal-title":"Int Med Case Rep J."},{"key":"1141_CR57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cgh.2009.11.023","volume":"8","author":"S Ben-Horin","year":"2010","unstructured":"Ben-Horin S, Yavzori M, Katz L, Picard O, Fudim E, Chowers Y, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1141_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85\u201395. https:\/\/doi.org\/10.1053\/j.gastro.2013.05.048 (quiz e14-5).","journal-title":"Gastroenterology."},{"issue":"96\u2013109","key":"1141_CR59","first-page":"e1","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(96\u2013109):e1.","journal-title":"Gastroenterology"},{"issue":"1","key":"1141_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12328-018-0906-9","volume":"12","author":"G Dragoni","year":"2019","unstructured":"Dragoni G, Le Grazie M, Orlandini B, Rogai F. Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol. 2019;12(1):1\u20139.","journal-title":"Clin J Gastroenterol"},{"key":"1141_CR61","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/ecco-jcc\/jjx176","volume":"12","author":"T Greener","year":"2018","unstructured":"Greener T, Boland K, Steinhart AH, Silverberg MS. The unfinished symphony: golimumab therapy for anti-tumour necrosis factor refractory Crohn\u2019s disease. J Crohn\u2019s Colitis. 2018;12:458\u201364.","journal-title":"J Crohn\u2019s Colitis."},{"key":"1141_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy192","author":"L Benoit","year":"2018","unstructured":"Benoit L, Mir O, Berveiller P. Treating ulcerative colitis during pregnancy: evidence of materno\u2013fetal transfer of golimumab. J Crohn\u2019s Colitis. 2018. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy192 .","journal-title":"J Crohn\u2019s Colitis."},{"key":"1141_CR63","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/art.38216","volume":"65","author":"A Lau","year":"2013","unstructured":"Lau A, Clark M, Harrison D, Geldhof A, Nissinen R, Sanders M. 2013 Annual meeting abstract supplement. Arthritis Rheum. 2013;65:S1\u20131331.","journal-title":"Arthritis Rheum"},{"key":"1141_CR64","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","volume":"13","author":"A Nesbitt","year":"2007","unstructured":"Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor \u03b1 agents. Inflamm Bowel Dis. 2007;13:1323\u201332.","journal-title":"Inflamm Bowel Dis"},{"key":"1141_CR65","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357:228\u201338.","journal-title":"N Engl J Med"},{"key":"1141_CR66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","volume":"116","author":"C Porter","year":"2016","unstructured":"Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016;116:7\u201312.","journal-title":"J Reprod Immunol"},{"issue":"2","key":"1141_CR67","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B, Flynn AD, Molt\u00f3 A, Flipo RM, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228\u201333. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212196 .","journal-title":"Ann Rheum Dis."},{"key":"1141_CR68","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.40508","volume":"70","author":"MEB Clowse","year":"2018","unstructured":"Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball AB, Cush JJ, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol (Hoboken, NJ). 2018;70:1399\u2013407.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)."},{"key":"1141_CR69","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3899\/jrheum.140189","volume":"42","author":"MEB Clowse","year":"2015","unstructured":"Clowse MEB, Wolf DC, F\u00f6rger F, Cush JJ, Golembesky A, Shaughnessy L, et al. Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol. 2015;42:2270\u20138.","journal-title":"J Rheumatol"},{"key":"1141_CR70","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","volume":"76","author":"ME Clowse","year":"2017","unstructured":"Clowse ME, F\u00f6rger F, Hwang C, Thorp J, Dolhain RJ, van Tubergen A, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1141_CR71","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","volume":"7","author":"K Ley","year":"2007","unstructured":"Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678\u201389.","journal-title":"Nat Rev Immunol"},{"key":"1141_CR72","volume-title":"Anti-adhesion molecule therapy for inflammatory bowel disease","author":"S Ghosh","year":"2010","unstructured":"Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Gastroenterol: Ther Adv; 2010."},{"issue":"6","key":"1141_CR73","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1053\/gast.1997.v112.pm9178682","volume":"112","author":"DG Binion","year":"1997","unstructured":"Binion DG, West GA, Ina K, Ziats NP, Emancipator SN, Fiocchi C. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 1997;112(6):1895\u2013907.","journal-title":"Gastroenterology."},{"key":"1141_CR74","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","volume":"24","author":"SC Park","year":"2018","unstructured":"Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol. 2018;24:1868\u201380.","journal-title":"World J Gastroenterol"},{"key":"1141_CR75","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"issue":"5","key":"1141_CR76","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","volume":"132","author":"SR Targan","year":"2007","unstructured":"Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE trial. Gastroenterology. 2007;132(5):1672\u201383.","journal-title":"Gastroenterology."},{"issue":"4","key":"1141_CR77","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438\u201346. https:\/\/doi.org\/10.1016\/S1474-4422(10)70028-4 .","journal-title":"Lancet Neurol."},{"key":"1141_CR78","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","volume":"71","author":"A Haghikia","year":"2014","unstructured":"Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891\u20135.","journal-title":"JAMA Neurol."},{"key":"1141_CR79","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/bdrb.20193","volume":"86","author":"NG Wehner","year":"2009","unstructured":"Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86:144\u201356.","journal-title":"Birth Defects Res B Dev Reprod Toxicol."},{"key":"1141_CR80","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458514546790","volume":"21","author":"N Ebrahimi","year":"2015","unstructured":"Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21:198\u2013205.","journal-title":"Mult Scler."},{"key":"1141_CR81","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12883-016-0674-4","volume":"16","author":"S Friend","year":"2016","unstructured":"Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri\u00ae (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16:150.","journal-title":"BMC Neurol."},{"issue":"5, S1","key":"1141_CR82","doi-asserted-by":"publisher","first-page":"S-170","DOI":"10.1016\/S0016-5085(14)60602-8","volume":"146","author":"U Mahadevan","year":"2014","unstructured":"Mahadevan U, Martin CF, Dubinsky M, Kane SV, Sands BE, Sandborn W. Exposure to anti-TNF\u03b1 therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry. Gastroenterology. 2014;146(5, S1):S-170. https:\/\/doi.org\/10.1016\/S0016-5085(14)60602-8 (abstr no A960).","journal-title":"Gastroenterology."},{"key":"1141_CR83","unstructured":"Natalizumab: PRESCRIBING INFORMATION [Internet] [cited 2019 Jan 15]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125104s106lbl.pdf ."},{"key":"1141_CR84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0890334414566237","volume":"31","author":"TE Baker","year":"2015","unstructured":"Baker TE, Cooper SD, Kessler L, Hale TW. Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Hum Lact. 2015;31:233\u20136.","journal-title":"J Hum Lact."},{"issue":"8","key":"1141_CR85","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1215734 .","journal-title":"N Engl J Med."},{"key":"1141_CR86","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369:711\u201321.","journal-title":"N Engl J Med"},{"issue":"618\u2013627","key":"1141_CR87","first-page":"e3","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan BG, Rutgeerts P, Colombel J-F, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(618\u2013627):e3.","journal-title":"Gastroenterology"},{"key":"1141_CR88","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1093\/ecco-jcc\/jjx180.199","volume":"12","author":"D Crawford","year":"2018","unstructured":"Crawford D, Friedman M. Safety analysis of vedolizumab during pregnancy: findings from a reproductive study in monkeys. J Crohn\u2019s Colitis. 2018;12:S129.","journal-title":"J Crohn\u2019s Colitis."},{"issue":"4, S1","key":"1141_CR89","doi-asserted-by":"publisher","first-page":"S91\u2013S92","DOI":"10.1016\/S0016-5085(16)30422-X","volume":"150","author":"U Mahadevan","year":"2016","unstructured":"Mahadevan U, Martin C, Kane SV, Dubinsky M, Sands BE, Sandborn W. Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO registry. Gastroenterology. 2016;150(4, S1):S91\u2013S92. https:\/\/doi.org\/10.1016\/S0016-5085(16)30422-X (abstr no A437).","journal-title":"Gastroenterology."},{"issue":"7","key":"1141_CR90","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/apt.13960","volume":"45","author":"U Mahadevan","year":"2017","unstructured":"Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(7):941\u201350. https:\/\/doi.org\/10.1111\/apt.13960 .","journal-title":"Aliment Pharmacol Ther."},{"key":"1141_CR91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ecco-jcc\/jjy142","volume":"13","author":"A Moens","year":"2019","unstructured":"Moens A, van Hoeve K, Humblet E, Rahier J-F, Bossuyt P, Dewit S, et al. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. J Crohns Colitis. 2019;13:12\u20138.","journal-title":"J Crohns Colitis."},{"issue":"752\u2013754","key":"1141_CR92","first-page":"e1","volume":"154","author":"M Julsgaard","year":"2018","unstructured":"Julsgaard M, Kjeldsen J, Bibby BM, Brock B, Baumgart DC. Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease. Gastroenterology. 2018;154(752\u2013754):e1.","journal-title":"Gastroenterology"},{"key":"1141_CR93","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ecco-jcc\/jjx120","volume":"12","author":"A Lahat","year":"2018","unstructured":"Lahat A, Shitrit AB-G, Naftali T, Milgrom Y, Elyakim R, Goldin E, et al. Vedolizumab levels in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2018;12:120\u20133.","journal-title":"J Crohns Colitis."},{"key":"1141_CR94","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/00054725-200407000-00023","volume":"10","author":"RL Jump","year":"2004","unstructured":"Jump RL, Levine AD. Mechanisms of natural tolerance in the intestine. Inflamm Bowel Dis. 2004;10:462\u201378.","journal-title":"Inflamm Bowel Dis"},{"key":"1141_CR95","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","volume":"448","author":"RJ Xavier","year":"2007","unstructured":"Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427\u201334.","journal-title":"Nature"},{"key":"1141_CR96","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.0105-2896.2004.00214.x","volume":"202","author":"CL Langrish","year":"2004","unstructured":"Langrish CL, McKenzie BS, Wilson NJ, De Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev. 2004;202:96\u2013105.","journal-title":"Immunol Rev."},{"key":"1141_CR97","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/00365520310000672","volume":"38","author":"OH Nielsen","year":"2003","unstructured":"Nielsen OH, Kirman I, R\u00fcdiger N, Hendel J, Vainer B. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol. 2003;38:180\u20135.","journal-title":"Scand J Gastroenterol"},{"key":"1141_CR98","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology. 2008;135:1130\u201341.","journal-title":"Gastroenterology"},{"key":"1141_CR99","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet (London, England). 2008;371:1675\u201384.","journal-title":"Lancet (London, England)."},{"key":"1141_CR100","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360.","journal-title":"N Engl J Med"},{"issue":"S2","key":"1141_CR101","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/jcag\/gwy009.109","volume":"1","author":"E Scherl","year":"2018","unstructured":"Scherl E, Jacobstein D, Murphy C, Ott E, Gasink C, Baumgart DC, et al. Pregnancy outcomes in women exposed to ustekinumab in the Crohn\u2019s disease clinical development program. J Can Assoc Gastroenterol. 2018;1(S2):166. https:\/\/doi.org\/10.1093\/jcag\/gwy009.109 (abstr no A109).","journal-title":"J Can Assoc Gastroenterol."},{"key":"1141_CR102","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.3748\/wjg.v20.i13.3495","volume":"20","author":"VW Huang","year":"2014","unstructured":"Huang VW. From conception to delivery: managing the pregnant inflammatory bowel disease patient. World J Gastroenterol. 2014;20:3495.","journal-title":"World J Gastroenterol"},{"key":"1141_CR103","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","unstructured":"G\u00f6testam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795\u2013810.","journal-title":"Ann Rheum Dis"},{"key":"1141_CR104","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273\u201387.","journal-title":"Immunol Rev"},{"key":"1141_CR105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","volume":"76","author":"M Coskun","year":"2013","unstructured":"Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK\/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1\u20138.","journal-title":"Pharmacol Res"},{"issue":"Pt 8","key":"1141_CR106","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","volume":"117","author":"JS Rawlings","year":"2004","unstructured":"Rawlings JS. The JAK\/STAT signaling pathway. J Cell Sci. 2004;117(Pt 8):1281\u20133.","journal-title":"J Cell Sci."},{"key":"1141_CR107","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40265-017-0755-8","volume":"77","author":"M Flamant","year":"2017","unstructured":"Flamant M, Rigaill J, Paul S, Roblin X. Advances in the development of janus kinase inhibitors in inflammatory bowel disease: future prospects. Drugs. 2017;77:1057\u201368.","journal-title":"Drugs."},{"key":"1141_CR108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","volume":"285","author":"T Kisseleva","year":"2002","unstructured":"Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK\/STAT pathway, recent advances and future challenges. Gene. 2002;285:1\u201324.","journal-title":"Gene"},{"key":"1141_CR109","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895\u2013905.","journal-title":"Arthritis Rheum"},{"key":"1141_CR110","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"KA Papp","year":"2015","unstructured":"Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949\u201361.","journal-title":"Br J Dermatol"},{"key":"1141_CR111","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med"},{"key":"1141_CR112","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","volume":"42","author":"ME Dowty","year":"2014","unstructured":"Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42:759\u201373.","journal-title":"Drug Metab Dispos"},{"key":"1141_CR113","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","volume":"24","author":"U Mahadevan","year":"2018","unstructured":"Mahadevan U, Dubinsky MC, Su C, Lawendy N, Jones TV, Marren A, et al. Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24:2494\u2013500.","journal-title":"Inflamm Bowel Dis"},{"key":"1141_CR114","unstructured":"Tofacitinib: prescribing information [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf ."},{"key":"1141_CR115","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","volume":"39","author":"MEB Clowse","year":"2016","unstructured":"Clowse MEB, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39:755\u201362.","journal-title":"Drug Saf"},{"key":"1141_CR116","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","volume":"16","author":"DB Beaulieu","year":"2018","unstructured":"Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol. 2018;16:99\u2013105.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1141_CR117","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaad.2011.04.030","volume":"65","author":"MM Heller","year":"2011","unstructured":"Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol. 2011;65:870.","journal-title":"J Am Acad Dermatol"},{"key":"1141_CR118","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","volume":"9","author":"CJ van der Woude","year":"2015","unstructured":"van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, et al. The second european evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohn\u2019s Colitis. 2015;9:107\u201324.","journal-title":"J Crohn\u2019s Colitis."},{"key":"1141_CR119","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ajg.2010.464","volume":"106","author":"U Mahadevan","year":"2011","unstructured":"Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SPL, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn\u2019s and colitis organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214\u201323.","journal-title":"Am J Gastroenterol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01141-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01141-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:55:45Z","timestamp":1608252945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01141-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":119,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01141-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"10 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to support the writing of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Cynthia Seow has received funds from Janssen, AbbVie, Takeda, Ferring, Shire and Pfizer for participating in speakers\u2019 bureaus, advisory boards, educational events, grants and for travel to associated meetings. No company had direct input into this manuscript. Sherman Picardo has no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}